NP47926 Biologic, Biosimilar’s and Methotrexate Injections
In plain English
The notice doesn't say
Who holds it now
Last won by Takeda UK Limited in Jul 2026.
- NP90726m Vedolizumab (Entyvio®)Takeda UK Limited
- HIV MedicinesAmarox Limited, Glenmark Pharmaceuticals Europe Ltd, Lupin Healthcare UK Ltd and 11 more £89.9m
What you're up against
- The last two awards went to different firms: this buyer has changed supplier before.
- 15 different firms won this buyer's 2 awards for this kind of work in 2026.
The notice as published
Supply of Biologics, Biosimilars and Methotrexate Injections to NHS Scotland. Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of infliximab subcutaneous injection to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents. Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of adalimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 7 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of etanercept to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of golimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of infliximab intravenous infusion to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 6 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of omalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of tocilizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of ustekinumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 9 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Supply of tildrakizumab to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents.